Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02888678
Other study ID # 741818
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 2016
Est. completion date May 31, 2018

Study information

Verified date June 2018
Source FHI 360
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates whether the integration of an Economic Strengthening program with an HIV-prevention education program produce synergistic effects on economic and health outcomes for South African youth ages 14-17 years old.


Description:

In South Africa, the overall HIV prevalence of 12.2% can be reviewed based on a number of factors: age, province, type of locality, race, economic household conditions, and marital status. Those to be reached through the ASPIRES intervention and evaluation are economically disadvantaged Black African youth, male and female, located in urban localities in Gauteng province, and are situated within a setting of high risk and vulnerability for HIV. The ASPIRES project is providing technical assistance to provide economic strengthening (ES) and HIV prevention education programming for adolescents. The ASPIRES ES intervention includes financial capability building through the provision of financial education in combination with access to appropriate youth-friendly savings mechanisms. The HIV prevention education intervention Vhutshilo 2.2 will be used in this study.

This study will assess whether the integration of an ES intervention with an HIV-prevention education intervention improves economic and health outcomes beyond singular interventions, estimate the resources required at the program level to support the ES and HIV-prevention education interventions; and describe whether the interventions were perceived as effective in addressing economic and health outcomes and to describe how and why the interventions were perceived as effective or not.

This study will enroll up to 2000 youth ages 14-17 and randomly assign them to either 1) ES intervention only, 2) HIV prevention intervention only, 3) combined ES and HIV intervention, or 4) no intervention.


Recruitment information / eligibility

Status Completed
Enrollment 1773
Est. completion date May 31, 2018
Est. primary completion date May 31, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 14 Years to 17 Years
Eligibility Inclusion Criteria:

- Beneficiary of Future Families in a study community

- Parent or guardian consent allowing adolescent to participate in the study

- Willing to sign or make their mark on an assent form

- Willing to provide contact information

- Only one adolescent is eligible per household

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Economic Strengthening (Impumelelo)
Economic Strengthening (Impumelelo): This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.
HIV Prevention Education (Vhutshilo 2.2)
HIV Prevention Education (Vhutshilo 2.2): This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy.

Locations

Country Name City State
South Africa community Based Recruitment Pretoria Gauteng

Sponsors (3)

Lead Sponsor Collaborator
FHI 360 Foundation for Professional Development, Future Families

Country where clinical trial is conducted

South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary STI prevalence Endline 1 Prevalence of gonorrhea, trichomoniasis or chlamydia infection (lab report) Nine months after baseline interview
Primary STI prevalence Endline 2 Prevalence of gonorrhea, trichomoniasis or chlamydia infection (lab report) eighteen months after baseline interview
Secondary Prevalence of pregnancy Endline 1 Prevalence of pregnancy among female participants (lab report) Nine months after baseline interview
Secondary Prevalence of pregnancy Endline 2 Prevalence of pregnancy among female participants (lab report) eighteen months after baseline interview
Secondary Percent of adolescents engaging in protective sexual behavior Endline 1 Percent of adolescents engaging in protective sexual behavior, defined as self-reported abstinence or consistent condom use (a condom used every time) over the past 6 months In the 6 month time period prior to the date of the follow up visit
Secondary Percent of adolescents engaging in protective sexual behavior Endline 2 Percent of adolescents engaging in protective sexual behavior, defined as self-reported abstinence or consistent condom use (a condom used every time) over the past 6 months In the 6 month time period prior to the date of the follow up visit
Secondary Percent of adolescents engaging in transactional sex in past 6 months Endline 1 self-reported In the 6 months prior to the date of the follow up visit
Secondary Percent of adolescents engaging in transactional sex in past 6 months Endline 2 self-reported In the 6 months prior to the date of the follow up visit
Secondary Percent of adolescents reporting two or more sexual partners in the past 6 months Endline 1 self-reported In the 6 months prior to the date of the follow up visit
Secondary Percent of adolescents reporting two or more sexual partners in the past 6 months Endline 2 self-reported In the 6 months prior to the date of the follow up visit
Secondary Mean HIV knowledge score Endline 1 HIV knowledge score calculated based on the answers to survey questions Nine months after baseline interview
Secondary Mean HIV knowledge score Endline 2 HIV knowledge score calculated based on the answers to survey questions Eighteen months after baseline interview
Secondary Mean financial literacy score Endline 1 Financial literacy score calculated based on the answers to survey questions Nine months after baseline interview
Secondary Mean financial literacy score Endline 2 Financial literacy score calculated based on the answers to survey questions eighteen months after baseline interview
Secondary Percent of adolescents participating in savings group Endline 1 Percent of adolescents participating in savings group (self report) Nine months after baseline interview
Secondary Percent of adolescents participating in savings group Endline 2 Percent of adolescents participating in savings group (self report) eighteen months after baseline interview
Secondary Percent of adolescents opening savings account Endline 1 Percent of adolescents opening savings account (self report) Nine months after baseline interview
Secondary Percent of adolescents opening savings account Endline 2 Percent of adolescents opening savings account (self report) eighteen months after baseline interview
Secondary Mean total amount of savings in past 1 year Endline 1 Mean total amount of savings starting from prior to enrollment in the study up to 9 months of participation in the study In the one year prior to the date of the 9 month follow up visit
Secondary Mean total amount of savings in past 1 year Endline 2 Mean total amount of savings in past 1 year reported by adolescents (self report) In the one year prior to the date of the 18 month follow up visit
Secondary Percent of adolescents saving for education Endline 1 Percent of adolescents saving for education (self report) Nine months after baseline interview
Secondary Percent of adolescents saving for education Endline 2 Percent of adolescents saving for education (self report) eighteen months after baseline interview
Secondary Percent of adolescents whose caregiver provided money for savings Endline 1 Percent of adolescents whose caregiver provided money for savings (self report) Nine months after baseline interview
Secondary Percent of adolescents whose caregiver provided money for savings Endline 2 Percent of adolescents whose caregiver provided money for savings (self report) eighteen months after baseline interview
Secondary Percent of adolescents who participate in household budgeting Endline 1 Percent of adolescents who participate in household budgeting (self report) Nine months after baseline interview
Secondary Percent of adolescents who participate in household budgeting Endline 2 Percent of adolescents who participate in household budgeting (self report) eighteen months after baseline interview
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2